Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for many patients with hematologic malignancies and marrow failure. The full potential of HSCT is limited by transplant related complications -particularly acute and chronic GVHD (cGVHD). Traditional means to control GVHD, particularly cGVHD, are only partially effective. Despite excellent control of acute GVHD, 50-70% of patients develop cGVHD. Chronic GVHD is the primary late complication of HSCT. The heterogeneity of manifestations and late onset has led to a situation where research lags behind clinical needs. The importance of cGVHD is increasingly relevant as 1) improvements in HSCT technology allow the use of older donors to transplant older patients, 2) the incidence of cGVHD increased due to greater use of peripheral blood as a stem cell source, and 3) improvements in supportive care result in less nonrelapse mortality and thus more patients alive in the late time periods when cGVHD occurs. This is an opportunity to embark on novel studies to leverage new information on the pathobiology of GVHD. The importance of B cells and regulatory T cells (Treg) is increasingly clear, but there has been little effort to directly manipulate B cell and Treg function in humans. We now know that B cells work with T cells in a coordinated fashion to produce cGVHD. Project 1 includes three Specific Aims (SA) including 5 projects to develop new strategies to prevent and treat GVHD. SA1a is a novel approach to prevent cGVHD in patients without active GVHD using monoclonal anti-CD20 to target the B cell component of cGVHD. In SA1b the goal is to eliminate calineurin inhibitors (CNI) from GVHD prophylaxis. CNI have undesirable intrinsic toxicity, and they inhibit Treg in a counterproductive fashion. By using CNI-free regimens, the expansion of Treg is facilitated to reduce both allo- and autoimmunity, and thus the overall risk of both acute and cGVHD. In SA 2 strategies to prevent a major complication of HSCT, hepatic VOD are assessed. In SA 3, two complementary approaches to treat steroid-resistant cGVHD will be evaluated: 1) by coordinately inhibiting both B and T cells with low dose anti-CD52 monoclonal antibody, and 2) by expansion of Treg with ultra low dose IL-2.

Public Health Relevance

The importance of cGVHD is increasingly relevant as 1) improvements in HSCT technology allow the use of older donors to transplant older patients, 2) the incidence of cGVHD increased due to greater use of peripheral blood as a stem cell source, and 3) improvements in supportive care result in less nonrelapse mortality and thus more patients alive in the late time periods when cGVHD occurs. This is an opportunity to embark on novel studies to leverage new information on the pathobiology of GVHD.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA142106-10
Application #
8468131
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
2015-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
10
Fiscal Year
2013
Total Cost
$263,342
Indirect Cost
$90,324
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Bachireddy, Pavan; Hainz, Ursula; Rooney, Michael et al. (2014) Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood 123:1412-21
Dubovsky, Jason A; Flynn, Ryan; Du, Jing et al. (2014) Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest 124:4867-76
Koreth, John; Kim, Haesook T; Nikiforow, Sarah et al. (2014) Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant 20:1516-21
Herrera, Alex F; Kim, Haesook T; Bindra, Bhavjot et al. (2014) A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant 20:1737-43
Gazourian, Lee; Rogers, Angela J; Ibanga, Ruby et al. (2014) Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Am J Hematol 89:404-9
Socié, Gérard; Ritz, Jerome (2014) Current issues in chronic graft-versus-host disease. Blood 124:374-84
Armand, Philippe; Kim, Haesook T; Virtanen, Johanna M et al. (2014) Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis. Biol Blood Marrow Transplant 20:1248-51
Alexander, Kylie A; Flynn, Ryan; Lineburg, Katie E et al. (2014) CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Invest 124:4266-80
Kim, Haesook T; Frederick, David; Armand, Philippe et al. (2014) White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. Am J Hematol 89:591-7
Pai, Chien-Chun Steven; Chen, Mingyi; Mirsoian, Annie et al. (2014) Treatment of chronic graft-versus-host disease with bortezomib. Blood 124:1677-88

Showing the most recent 10 out of 68 publications